vimarsana.com
Home
Live Updates
Dr Sabari on the FDA Approval of Frontline Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC : vimarsana.com
Dr Sabari on the FDA Approval of Frontline Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC : vimarsana.com
Dr Sabari on the FDA Approval of Frontline Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC
Joshua K. Sabari, MD, discusses the FDA approval of frontline amivantamab plus chemotherapy for NSCLC harboring EGFR exon 20 insertion mutations.
Related Keywords
United States ,
Joshuak Sabari ,
,
York University Grossman School Of Medicine ,
Department Of Medicine ,
New York University Grossman School ,